Bibliography
- Gulick R , RibaudoH, ShikumaCet al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.N. Engl. J. Med.350(18), 1850–1861 (2004).
- Khanlou H , GuyerB, FarthingC: Efficacy of tenofovir as Intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.JAMA38(5), 627–628 (2005).
- Kumar PN , Rodriguez-FrenchA, ThompsonMAet al.: A prospective 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine /stavudine /nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.HIV Med.7(2), 85–98 (2006).
- Bartlett J , DeMasiR, QuinnJ, MoxhamC, RousseauF: Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults.AIDS15(11), 1369–1377 (2001).
- Orkin C , StebbingJ, NelsonMet al.: A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).J. Antimicrob. Chemother.55(2), 246–251 (2005).
- Moyle G , HiggsC, TeagueAet al.: An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen for individuals initiating antiretroviral therapy.Antivir. Ther.11(1), 73–78 (2006).
- Cohen C , ElionR, RedfieldRet al.: 48 week analysis of efficacy and safety of once-daily (QD) abacavir/lamivudine/zidovudine (Trizivir) plus Tenofovir (TDF). Presented at: 45th International Conference on Antimicrobial Agents and Chemotherapy.Washington DC, USA, 16–19December2005 (Abstract H-521).
- De Truchis Force G , WelkerYet al.: Efficacy and safety of a quadruple combination Combivir and abacavir and efavirenz in antiretroviral treatment-naïve adults: La Francilienne.J. Acquir. Immune Defic. Syndr.31(2), 178–182 (2002).
- Markowitz M , Hill-ZabalaC, LangJet al., for the ESS40013 Study Team. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/ zidovudine alone in antiretroviral-naive HIV-1-infected patients.J. Acquir. Immune Defic. Syndr.39(3), 257-264 (2005).
- Mallolas J , RieraM, DomingoPet al.: Induction-maintenance antiretroviral therapy with Trizivir plus either efavirenz or lopinavir/ritonavir: results of a multicentre randomized clinical trial at 72 weeks. Accepted as an oral presentation presented at: 8th International Congress on Drug Therapy in HIV Infection.Glasgow, UK, 12–16November2006.
- De Truchis P , ForceG, ChemlalKet al.: An open-label study to evaluate safety and efficacy of switching to TZV maintenance treatment after first-line quadruple induction therapy: SUBURBS.Proceedings of the 8th European Conference on Clinical Aspects and Treatment of HIV infection.Athens, Greece, 29–31October2001 (Abstract 76).
- Hammer SM , SaagMS, SchechterMet al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society – USA panel. JAMA 296, 827–84315 (2006).
- Martinez E , ArnaizJA, PodzamczerDet al.: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.N. Eng. J. Med.349(11), 1036–1046 (2003).
- Opravil M , HirschelB, LazzarinAet al.: A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.J. Infect. Dis.185(9), 1251–1260 (2002).
- Keiser PH , SensionMG, DeJesusEet al., for the ESS40003 Study Team. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.BMC Infect. Dis.5(1), 2 (2005).
- Katlama C , FenskeS, GazzardBet al.: TRIZAL study: switching from successful HAART to Trizivir™ abacavir-lamivudine-zidovudine combination tablet: 48 weeks efficacy, safety and adherence results.HIV Med.4(2), 79–86 (2003).
- Katlama C , GazzardB, MallolasJet al.: Comparison of metabolic abnormalities 48 weeks after switching form highly active antiretroviral therapy containing non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.AIDS17(12), 1885–1886 (2003).
- Rodriguez A , Hill-ZabalaC, SloanLet al.: Patients experiencing early virological failure on a protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and lamivudine can be successfully treated with a quadruple-nucleoside regimen.J. Acquir. Immune Defic. Syndr.41(1), 127–129 (2006).
- Ruane P , LuberA, GaultierCet al.: Efficacy of Trizivir (TZV) and tenofovir (TDF) as HAART for HIV infected patients with current underlying reverse transcriptase (RT) resistance. Presented at: XV International AIDS Conference.Bangkok, Thailand, 11–16 July 2004 (Abstract No TuPeB4600).
- D‘Ettorre G , MastroianniCM, MassettiAPet al.: Switching from protease inhibitors to single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.AIDS19(8), 841–842 (2005).
- Latham V , StebbingJ, MandaliaSet al.: Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.J. Antimicrob. Chemother.56(1), 186–189 (2005).
- Chittick GE , GillotinC, McDowellJAet al.: Abacavir: absolute bioavailability, bioequivalence of three oral formulation and effect of food.Pharmacotherapy19(8), 932–942 (1999).
- Bart PA , RizzardiPG, GallantSet al.: Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.Ther. Drug Monit.23(5), 553–555 (2001).
- Melby T , TortellS, ThorbornDet al.: Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients failing ABC/COM.Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections.San Francisco, USA, 8–11February2004 (Abstract 52).
- Escaut L , LiotierJY, AlbengresEet al.: Abacavir rechallenge has to be avoid in case of hypersensitivity reaction.AIDS13(11), 1419–1420 (1999).
- Hetherington S , McGuirkS, PowellGet al.: Hypersensitivity reactions during therapy with nucleoside reverse transcriptase inhibitor abacavir.Clin. Ther.23(10), 1603–1614 (2001).
- Mallal S , NolanD, WittCet al.: Association between the presence of HLA-B5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.Lancet359(9308), 727–732 (2002).
- Rauch A , NolanD, MartinA, McKinnonE, AlmeidaC, MallalS. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.Clin. Infect. Dis.43(1), 99–102 (2006).
- Rauch A , NolanD, MartinAet al.: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian Human Immunodeficiency Virus Cohort.Clin. Infect. Dis.43(1), 99–102 (2006).
- Phillips EJ , WongGA, KaulRet al.: Clinical and immunogenetic correlates of abacavir hypersensitivity.AIDS19(9), 979–981 (2005).
- Martin AM , NolanD, GaudieriSet al.: Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and haplotypic Hsp70-Hom variant.Proc. Natl Acad. Sci. USA101(12), 4180–4185 (2004).
- Chene G , AngeliniE, CotteLet al.: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.Clin. Infect. Dis.34(5), 649–657 (2002).
- Amin J , MooreA, CarrAet al.: Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection. Ozcombo 1 and 2.HIV Clin. Trials4(4), 252–261 (2003).
- Moyle GJ , DattaD, MandaliaS, MorleseJ, AsboeD, GazzardBG: Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.AIDS16, 1341–1349 (2002).
Websites
- GlaxoSmithKline - GlaxoSmithKline, Trizivir™ Product Information, March 2006. http://us.gsk.com/products/assets/ us_trizivir.pdf
- The Panel on Clinical Practices for Treatment of HIV Infection, convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (2006). http://AIDSinfo.nih.gov